<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902021000100007</article-id>
<article-id pub-id-type="doi">10.29262/ram.v68i1.826</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Rituximab como tratamiento de pénfigo refractario en pacientes mexicanos]]></article-title>
<article-title xml:lang="en"><![CDATA[Rituximab as treatment for refractory pemphigus in Mexican patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-Meza]]></surname>
<given-names><![CDATA[Samantha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Arriaga]]></surname>
<given-names><![CDATA[León Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barrón-Tapia]]></surname>
<given-names><![CDATA[María Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estrada-Aguilar]]></surname>
<given-names><![CDATA[Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional Lic. Adolfo López Mateos Servicio de Dermatología]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Pedregal Servicio de Medicina Interna ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<volume>68</volume>
<numero>1</numero>
<fpage>7</fpage>
<lpage>11</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902021000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902021000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902021000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  El pénfigo es una enfermedad autoinmune crónica y recalcitrante que afecta piel y mucosas. El tratamiento de primera línea son los corticosteroides sistémicos, aunque hay pacientes refractarios a estos y a otros inmunosupresores. Como alternativa, desde el año 2000 se ha utilizado el rituximab con buenos resultados, pero sin información de su comportamiento en población mexicana.  Objetivo:  Evaluar la respuesta clínica al tratamiento con rituximab en pacientes mexicanos con pénfigo.  Métodos:  Se trató de un estudio transversal, retrospectivo en un hospital de tercer nivel, en el que se incluyeron pacientes con pénfigo moderado-severo tratados con rituximab entre 2007 y 2020.  Resultados:  Se obtuvieron seis expedientes de pacientes con diagnóstico de pénfigo, cuatro presentaron la variedad vulgar y dos, la variedad foliácea; todos recibieron tratamiento sistémico inmunosupresor previo al rituximab. Los seis pacientes tuvieron remisión de la enfermedad en un promedio de 12.5 semanas.  Conclusión: El rituximab para el tratamiento de pacientes con pénfigo moderado-severo refractario a tratamiento inmunosupresor demostró ser de gran utilidad y logró un control de la enfermedad a mediano plazo, sin efectos adversos severos ni idiosincráticos en la población mexicana estudiada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Pemphigus (Pm) is a chronic and recalcitrant autoimmune disease that affects the skin and mucous membranes. The first line of treatment are systemic corticosteroids; however, there are patients who are refractory to them, as well as to other immunosuppressants. Rituximab has been used as a successful alternative since 2000 with good results but without information on its behavior in the Mexican population.  Objective: To assess the clinical response to treatment with rituximab in Mexican patients with pemphigus.  Methods:  This was a cross-sectional, retrospective study in a tertiary hospital, which included patients with moderate-severe pemphigus who had been treated with rituximab from 2007 to 2020.  Results:  Six medical records of patients diagnosed with pemphigus were obtained; four of them with Pm vulgaris, and two of them with pemphigus foliaceus; all patients had received systemic immunosuppressive therapy prior to rituximab. All six patients went into remission of the disease in an average of 12.5 weeks.  Conclusion:  The use of rituximab for the treatment of patients with moderate-severe Pm who were refractory to immunosuppressive therapy proved to be very useful, and control of the disease was achieved in the medium term, without severe or idiosyncratic adverse effects in the analyzed Mexican population.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Pénfigo]]></kwd>
<kwd lng="es"><![CDATA[Rituximab]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad autoinmune]]></kwd>
<kwd lng="en"><![CDATA[Pemphigus]]></kwd>
<kwd lng="en"><![CDATA[Rituximab]]></kwd>
<kwd lng="en"><![CDATA[Autoimmune disease]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab as first-line treatment of pemphigus]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10083</numero>
<issue>10083</issue>
<page-range>1956-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="">
<collab>Federación Mexicana de Enfermedades Raras</collab>
<source><![CDATA[México: Pénfigo vulgar]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harman]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Exton]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Groves]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Hampton]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mohd Mustapa]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Setterfield]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Yesudian]]></surname>
<given-names><![CDATA[PD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[British Association of Dermatologists&#8217; guidelines for the management of pemphigus vulgaris 2017]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2017</year>
<volume>177</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1170-201</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daneshpazhooh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Balighi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmoudi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tavakolpour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abedini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Soori]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iranian guideline for rituximab therapy in pemphigus patients]]></article-title>
<source><![CDATA[Dermatol Ther.]]></source>
<year>2019</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kridin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zelber-Sagi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for lethal outcome in patients with pemphigus: a retrospective cohort study]]></article-title>
<source><![CDATA[Eur J Dermatol.]]></source>
<year>2018</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-37</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kridin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sagi]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality and cause of death in patients with pemphigus]]></article-title>
<source><![CDATA[Acta Derm Venereol.]]></source>
<year>2017</year>
<volume>97</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>607-11</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mimouni]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gdalevich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Katzenelson]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pemphigus, analysis of 155 patients]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol.]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>947-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Prost-Squarcioni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ingen-Housz-Oro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Joly]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Centre de Référence des Maladies Bulleuses Auto-immunes (MALIBUL), et al. [Update of the French recommendations for the management of pemphigus]]]></article-title>
<source><![CDATA[Ann Dermatol Venereol]]></source>
<year>2019</year>
<volume>146</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>279-86</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joly]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maho-Vaillant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prost-Squarcioni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hebert]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Houivet]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Musette]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[French Study Group on Autoimmune Bullous Skin Diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10083</numero>
<issue>10083</issue>
<page-range>2031-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rashid]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lamberts]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van Maanen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effectiveness of rituximab in pemphigus, and the benefit of additional maintenance infusions: daily practice data from a retrospective study]]></article-title>
<source><![CDATA[J Am Acad Dermatol.]]></source>
<year>2020</year>
<volume>83</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1503-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
